Pay in 4 interest-free payments of $6.90 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Buyer Takeaway: Screenshot the cancellation terms before you pay
Recently, Altimmune reported interim data for its weekly injectable GLP-1/glucagon dual agonist (pemvidutide) in a Phase 2 trial--disappointing levels of discontinuations sent the stock tumbling 55%
Proposed mechanisms of GLP-1RA-induced acute pancreatitis include pancreatic duct gland hyperplasia, pancreatic ductal obstruction leading to proinflammatory reactions, acinar cell hypertrophy, and pancreatic vascular injury.36 Additionally, another mechanism seen with the use of these drugs could be the increased risk of gallbladder or biliary diseases, especially when used in higher doses, for longer periods of time, and for weight loss.37 Previous animal studies suggested a risk of acute pancreatitis after GLP-1RA-based treatment.38 In addition, an initial analysis of the Food and Drug Administration's (FDA) adverse event reporting databases suggested an increased risk for acute pancreatitis with GLP-1RA-based therapy.39 It is important to note that this type of data analysis may not be the ideal method for comparing adverse event rates between medications
This enhances mitochondrial function and reduces mitochondrial DNA leakage, resulting in decreased inflammatory cytokine release and improved vascular integrity in the retina (He et al., 2024)
That said, peptide therapies are an area of ongoing study, individual responses vary, and we screen for conditions and medications that change the picture
